Amgen Inc. (AMGN) is currently trading at $414.61. Based on 29 Wall Street analysts, the average target price is $389.22, implying a 6.1% downside. The consensus recommendation is HOLD.

Over the past 30 days, the feed records 1 target raise and 1 target cut for AMGN. Over the past 90 days, the feed records 28 target raises and 2 target cuts for AMGN.

AMGN

Amgen Inc.

HealthcareOpinion: hold

Opinion Criteria: Based on the consensus of Wall Street analysts. Strong Buy (1.0-1.5), Buy (1.5-2.5), Hold (2.5-3.5), Sell (3.5-4.5), Strong Sell (4.5-5.0).

Price (USD)

$414.61

Consensus target price range

Low–high band from analyst PT changes in the last 3 months; median & sample mean vs current price

LowHigh
$230.00$460.00
Current $414.61
Median: $400.00Mean: $389.48Current: $414.61

Recent price target updates (latest 80)

  • HSBCSep 10, 2026

    PT action: Lowers

    $445.00 → $425.00

  • BMO CapitalSep 8, 2026

    PT action: Maintains

    $450.00 → $450.00

  • Cantor FitzgeraldSep 8, 2026

    PT action: Maintains

    $400.00 → $400.00

  • Wells FargoSep 4, 2026

    PT action: Raises

    $400.00 → $435.00

  • Piper SandlerAug 20, 2026

    PT action: Raises

    $427.00 → $457.00

  • Morgan StanleyAug 19, 2026

    PT action: Raises

    $351.00 → $362.00

  • Argus ResearchAug 19, 2026

    PT action: Raises

    $375.00 → $460.00

  • MizuhoAug 18, 2026

    PT action: Raises

    $303.00 → $352.00

  • Cantor FitzgeraldAug 18, 2026

    PT action: Raises

    $350.00 → $400.00

  • BarclaysAug 14, 2026

    PT action: Raises

    $360.00 → $380.00

  • GuggenheimAug 10, 2026

    PT action: Raises

    $343.00 → $388.00

  • CitigroupAug 7, 2026

    PT action: Raises

    $345.00 → $405.00

  • BernsteinAug 6, 2026

    PT action: Raises

    $335.00 → $345.00

  • BairdAug 5, 2026

    PT action: Raises

    $215.00 → $230.00

  • Canaccord GenuityAug 5, 2026

    PT action: Raises

    $366.00 → $384.00

  • B of A SecuritiesAug 5, 2026

    PT action: Raises

    $312.00 → $317.00

  • Goldman SachsAug 5, 2026

    PT action: Raises

    $427.00 → $450.00

  • UBSAug 5, 2026

    PT action: Raises

    $420.00 → $440.00

  • Morgan StanleyAug 5, 2026

    PT action: Raises

    $333.00 → $351.00

  • TD CowenAug 5, 2026

    PT action: Raises

    $420.00 → $452.00

Band uses only the revised target (Current column) from firm actions dated within the last 3 months—not the Prior price.

Avg Target

$389.22

Based on 29 analysts

Analyst Recommendations

Buy (12)Hold (17)Sell (5)

Upside

-6.12%

Market Cap

$224.15B

Financial & Investment Metrics

Next Earnings Date
Nov 3, 2026D-38
P/E Ratio (TTM)25.77
Forward P/E16.96
P/B Ratio19.18
Dividend Yield2.43%
Return on Equity (ROE)91.47%
Operating Margin35.55%
Debt to Equity490.28
Beta (Volatility)0.43
52 Week Range$270.67 - $447.03
LowCurrent: $414.61High

Latest News

Daily editorial mentioning AMGN

Price target moves

AMD Target Hiked to $550 as Utilities Face Sector-Wide Price Cuts

The corporate profit machine continues to churn out mixed signals, and Wall Street's sell-side desks are busy adjusting their goalposts to match. According to our latest 275-stock watchlist data compiled as of August 6, 2026, at 12:03 AM UTC, we are seeing an even split in recent sentiment. Over the past 14 days, the ledger recorded exactly 12 target price upgrades and 12 downgrades. This neat balance masks some highly volatile adjustments underneath, particularly in high-growth technology and defensive utility names.

Upgrades and downgrades

A two-week window of revisions reveals a stark divergence between aggressive growth targets in technology and a quiet retreat from defensive sectors.

The most eye-catching move comes from DA Davidson, which aggressively lifted its target price on AMD from $425 to $550. That massive $125 jump leaves the chipmaker with an implied upside of 20.1%, signaling that some analysts see plenty of room for expansion despite the stock's recent run. One name worth isolating on the opposite end of the sentiment spectrum is Amgen (AMGN). Both UBS and TD Cowen revised their price targets upward—UBS going from $420 to $440 and TD Cowen pushing from $420 to $452. Yet, despite these higher targets, AMGN carries a negative implied upside of -12.5%. That spread matters because it shows the stock has run up so fast that even these freshly upgraded targets sit well below current market levels.

Meanwhile, consumer names are feeling some pressure. McDonald's (MCD) saw two separate downward revisions, with RBC Capital trimming its target from $305 to $295, and Keybanc dropping its figure from $315 to $305. Over in the real estate space, SBAC was cut by Truist Securities from $248 to $238, though it still holds an implied upside of 28.7%.

Ticker Firm Dir Prior→Current
AMD DA Davidson up $425 → $550
AMGN TD Cowen up $420 → $452
PEG Citigroup down $91 → $84
MCD RBC Capital down $305 → $295

The defensive utility sector faced a coordinated wave of target trims. Citigroup lowered American Electric Power (AEP) from $148 to $142, while also slashing Public Service Enterprise Group (PEG) from $91 to $84. Wells Fargo also cut PEG, though more conservatively, from $91 to $89. Duke Energy (DUK) was not spared either, with BMO Capital and Barclays both dropping their targets to $132. It appears analysts are reassessing the premium they are willing to pay for steady utility dividends as broader economic conditions shift.

Limits of the data

These target adjustments offer valuable clues about institutional sentiment, but they come with built-in blind spots that investors should not ignore.

First, price targets are fundamentally lagging indicators. Analysts frequently adjust their targets after a company reports earnings or when a macroeconomic shift has already occurred, meaning these revisions often reflect past performance rather than predictive foresight. The Amgen anomaly is a perfect example of this lag, where the stock price has outpaced the analysts' ability to recalculate their models in real time.

Second, an individual firm's upgrade does not represent the consensus mean. When DA Davidson sets a $550 target for AMD, it represents one optimistic voice on the street, not the average expectation of all covering analysts. The consensus mean target acts as a smoothing mechanism, diluting extreme outer-bound targets to provide a more conservative baseline. Finally, these figures do not account for sudden market-wide liquidity shifts or geopolitical events that can render a 12-month price target obsolete overnight. Relying solely on these revisions without looking at underlying balance sheets can leave market participants catching falling knives or missing extended rallies.

Read article →

Insider Sentiment Index (Last 6 Months)

Counts and listings exclude stock awards, gifts, and option exercises—open-market purchases and sales only.

Buy vs Sell (Count)

Insider Buys: 0Insider Sells: 10

Whale Trades (C-Level Large Buys)

No major insider buying detected recently.

Recent Insider Transactions

DateNamePositionTransactionShares
8/13/2026KHOSLA RACHNAOfficerSale at price 412.57 - 416.43 per share.3,252
8/6/2026GRYGIEL NANCY AOfficerSale at price 402.16 per share.2,970
8/6/2026MILLER DEREKOfficerSale at price 402.54 per share.3,890
5/4/2026GRYGIEL NANCY AOfficerSale at price 323.73 per share.1,237
2/26/2026SANTOS ESTEBANOfficerSale at price 379.12 per share.54,792
2/19/2026BUSCH MATTHEW C.OfficerSale at price 375.79 per share.1,000
11/20/2025GRYGIEL NANCY AOfficerSale at price 337.26 per share.3,139
11/12/2025KHOSLA RACHNAOfficerSale at price 336.24 per share.890
11/12/2025GORDON MURDOOfficerSale at price 336.83 per share.6,879
8/20/2025GRYGIEL NANCY AOfficerSale at price 296.98 per share.1,267

Frequently Asked Questions

Q. What is the current target price and upside for AMGN?

A. The current target price for Amgen Inc. is $389.22, which implies a 6.1% downside from the current price of $414.61. This is based on the consensus of 29 Wall Street analysts.

Q. What is the current analyst recommendation for AMGN?

A. Currently, there are 4 Strong Buy, 8 Buy, 17 Hold, 3 Sell, and 2 Strong Sell ratings. The overall consensus is HOLD.

Q. Are insiders buying AMGN stock recently?

A. Over the past 6 months, there have been 0 insider buys and 10 insider sells. Insider selling is more prominent recently.

Other Promising Stocks in Healthcare

Data provided by Yahoo Finance. This information is for informational purposes only and does not constitute investment advice. We bear no legal responsibility for any investment decisions made based on this data.

Read full disclaimer →